Celldex stock falls after phase 2 trial misses key endpoints By Investing.com
Celldex Therapeutics (NASDAQ:CLDX) shares fell about 13% after hours after Phase 2 topline results for barzolvolimab in prurigo nodularis missed the primary endpoint (Worst Itch Numeric Rating Scale improvement at Week 12) and key secondary endpoints at both doses. The company is discontinuing the study but plans further Phase 3 readouts, including chronic spontaneous urticaria in Sep-Oct 2026.
How this was made
The 30-second read
Why it matters
The immediate tradable takeaway is the clinical readout failure and program stop in prurigo nodularis, which can drive further de-risking and valuation compression even as other trials continue.
Market read
A clear Phase 2 miss with discontinuation is a direct negative catalyst for CLDX, with attention shifting to later Phase 3 topline dates.
What to watch
The stock reaction may over-discount the failed indication versus the company’s stated upcoming Phase 3 topline timelines (chronic spontaneous urticaria in Sep-Oct 2026), which could re-rate the risk profile if results are positive.
Background
The article reports topline Phase 2 results for barzolvolimab in prurigo nodularis, including endpoint performance and the resulting discontinuation decision.
Ticker impact
Celldex shares fell after Phase 2 barzolvolimab in prurigo nodularis missed the primary and key secondary endpoints, prompting study discontinuation.
Bearish bias for CLDX into the next read-through, with volatility likely until upcoming Phase 3 topline milestones.
The article states the trial missed both primary and key secondary endpoints and Celldex is discontinuing the program in that indication, which typically pressures valuation and sentiment.
Market effects
Reinforces the high attrition risk in dermatology immunology trials and may pressure sentiment toward similar mast-cell-targeting approaches.
Limited, mostly company-specific impact within US biotech/biopharma sentiment.
Low; the catalyst is specific to Celldex’s program and does not indicate a broader global regulatory or market shift.
Counterpoint
Mast-cell depletion without symptom improvement suggests a mechanism mismatch for prurigo nodularis, but it does not necessarily invalidate barzolvolimab’s potential in other immune-mediated indications.
Key entities
- companyCelldex Therapeutics
NASDAQ-listed biotech whose Phase 2 barzolvolimab trial in prurigo nodularis missed endpoints and was discontinued.
- drugbarzolvolimab
Monoclonal antibody targeting mast cells; showed mast-cell depletion but no itch/lesion improvement vs placebo in the trial.
